Abstract Body

Background: BCA2 (Breast Cancer-Associated gene 2, Rabring7) is an E3 ubiquitin ligase that was identified as a co-factor in the restriction imposed by tetherin on HIV-1, lacking antiviral activity in the absence of tetherin. Contrary to this model, we found that BCA2 also possesses tetherin-independent antiviral activity, which leads to a reduction in the cellular levels of Gag, and therefore, in the amount of virus particles released from cells. Methodology: Virus release assays (p24 ELISA) were performed from tetherin-deficient cells transiently transfected with HIV proviral DNA and constructs coding for tetherin, BCA2, or BCA2 mutants. To explore if BCA2 promotes the degradation of Gag, similar assays were performed in the presence of proteasomal (ALLN, clasto-lactacystin-β-lactone) and lysosomal inhibitors (chloroquine, pepstatin, leupeptin, E64). To investigate if BCA2 promotes Gag ubiquitination, cells were engineered to express Gag and BCA2. The levels of Ub-Gag were determined by immunoprecipitation followed by western blotting, using an Ubiquitin-specific antibody. Next, Gag was tested for an interaction with BCA2 by co-immunoprecipitation. The role of endogenous BCA2 in virus release and replication was investigated by shRNA knockdowns. Finally, the effects of BCA2 on the subcellular distribution of Gag were evaluated by confocal microscopy. Results: Expression of BCA2 in tetherin-deficient cells caused a ~3-fold decrease in virus release. Western blot analyses indicated that this corresponds to a defect in Gag expression, with no effects on the levels of other viral proteins. Our binding and ubiquitination assays showed that BCA2 interacts with Gag through the Matrix region, and that BCA2 promotes Gag ubiquitination. The addition of lysosomal inhibitors to BCA2-expressing cells significantly restored Gag levels and virus release. The targeted depletion of BCA2 resulted in a substantial increase in virus release (5-fold more) and virus replication (10-fold more). Finally, cellular imaging assays revealed that BCA2 induces drastic changes in the subcellular distribution of Gag, which is primarily present in endolysosomal compartments. Conclusions: (1) BCA2 has tetherin-independent antiviral activity; (2) BCA2 promotes the ubiquitination and lysosomal degradation of HIV-1 Gag; and (3) the targeted depletion of BCA2 in tetherin-deficient cells increases virus release and replication, indicating that endogenous BCA2 possesses antiviral activity. These results indicate that BCA2 is an important antiviral factor that promotes the degradation of HIV-1 Gag, thereby, impairing virus assembly.